Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E20.65 EPS (ttm)7.55 Insider Own0.10% Shs Outstand758.25M Perf Week0.45%
Market Cap118.20B Forward P/E14.54 EPS next Y10.72 Insider Trans-8.16% Shs Float756.22M Perf Month-8.78%
Income5.81B PEG1.72 EPS next Q2.36 Inst Own81.70% Short Float1.13% Perf Quarter-0.26%
Sales20.77B P/S5.69 EPS this Y0.90% Inst Trans-1.07% Short Ratio2.44 Perf Half Y-1.41%
Book/sh36.16 P/B4.31 EPS next Y9.94% ROA8.30% Target Price186.27 Perf Year14.52%
Cash/sh39.56 P/C3.94 EPS next 5Y12.00% ROE22.10% 52W Range125.31 - 180.97 Perf YTD-0.67%
Dividend3.16 P/FCF18.79 EPS past 5Y8.20% ROI10.20% 52W High-13.86% Beta0.62
Dividend %2.03% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin79.90% 52W Low24.40% ATR6.03
Employees17900 Current Ratio5.50 Sales Q/Q3.70% Oper. Margin36.80% RSI (14)43.48 Volatility5.57% 3.37%
OptionableYes Debt/Eq1.16 EPS Q/Q7.00% Profit Margin28.00% Rel Volume1.32 Prev Close155.72
ShortableYes LT Debt/Eq1.12 EarningsJul 30 AMC Payout36.60% Avg Volume3.51M Price155.89
Recom2.40 SMA20-5.73% SMA50-3.60% SMA200-2.06% Volume4,647,491 Change0.11%
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Aug-28-15 04:10PM  Amgen wins FDA approval for cholesterol drug Repatha at bizjournals.com
03:34PM  Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool at Barrons.com
12:56PM  Smith & Wesson powers ahead on strong sales at Financial Times
12:12PM  Amgen v. Regeneron: Everyone Wins? at Barrons.com
10:35AM  Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
10:25AM  How Amgen Can Disrupt the Market for Cholesterol Drugs at 24/7 Wall St.
08:37AM  Time to Buy Amgen After Newly Approved Drug? at TheStreet
07:46AM  Early movers: BIG, MYL, FCX, BGS, FB, ADSK & more at CNBC
07:32AM  U.S. stocks set to fall as volatile week leaves investors wary at MarketWatch
06:51AM  Aug. 28 Premarket Briefing: 10 Things You Should Know
06:00AM  Amgen approved for pricey new drug
03:05AM  PRESS DIGEST- New York Times business news - August 28 Reuters
Aug-27-15 11:13PM  FDA Approves Amgens Cholesterol-Lowering Drug Repatha at The Wall Street Journal
10:07PM  The New Cholesterol Lowering Drugs Epitomize The Drug Pricing Battles at Forbes
09:10PM  Amgen wins approval for second biotech cholesterol drug
08:56PM  FDA approves Amgen cholesterol-lowering drug Repatha for some patients at Los Angeles Times
07:33PM  FDA Approves Amgen's Cholesterol Drug at The Wall Street Journal
06:49PM  Amgen's Repatha OK'd With Similar Label To Praluent at Investor's Business Daily
06:43PM  FDA approves Amgen's cholesterol-lowering drug Repatha Reuters
05:50PM  FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha (evolocumab) PR Newswire
05:22PM  FDA approves Amgen's cholesterol drug
05:17PM  FDA approves Amgen's cholesterol drug Repatha Reuters
05:14PM  Amgen Cholesterol Drug Wins U.S. Approval to Treat Some Patients at Bloomberg
02:31PM  Cholesterol drug wars
11:38AM  FDA lays out naming rules for lower-cost biotech drugs
11:02AM  'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure
06:28AM  Cholesterol drug wars: Amgen
Aug-26-15 05:50PM  Amgen files for FDA approval for drug to treat dialysis patients at bizjournals.com +6.05%
08:55AM  Short Sellers Become More Focused in Major Biotechs at 24/7 Wall St.
08:55AM  Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
07:00AM  High-Quality Stocks on Sale at Morningstar
Aug-25-15 01:13PM  Amgen files for approval of parathyroid disorder drug
11:25AM  AMAG is a Hidden Biotech Gem That is Exploding
09:15AM  Amgen To Present New Long-Term Repatha (Evolocumab) Data Analysis At ESC Congress 2015 PR Newswire
09:02AM  Amgen Files for U.S. Approval of Therapy for Dialysis Patients at The Wall Street Journal
09:00AM  Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) PR Newswire
Aug-24-15 02:25PM  Biotechs rally back
01:29PM  Business events scheduled for Tuesday
12:17PM  US 'big four' biotechs lead sector tumble into bear market at Financial Times
11:26AM  A Buying Opportunity For Regeneron: RBC at Barrons.com
06:53AM  Biotech blues despite 12% gain YTD
06:15AM  Biogen Pipeline Doesn't Justify High Valuation at Barrons.com
Aug-22-15 01:58AM  Next Week at Barrons.com
Aug-21-15 05:49PM  Analysis, Not Fear, Is Needed When A New Bull Run Begins
04:13PM  How Big Biotech Spents It's Money at Barrons.com
01:15PM  Why Medivation is a Stunning Biotech Opportunity
10:43AM  4 Reasons To Keep An Eye On Biotech Stock Celgene
03:06AM  Will Orkambi Be a Game Changer for Vertex?
Aug-20-15 05:54PM  Dividend cuts for big oil?
05:42PM  Cholesterol war heats up
05:00PM  3 ways to play biotech's beatdown
01:03PM  Key Financial Ratios to Analyze Biotech Companies at Investopedia
01:00PM  Amgen: Waiting for Clarity on Generic Biotech at Barrons.com
11:06AM  Regeneron Outperforms with Better 2Q15 Results
11:02AM  This Is a Concern That Amgen Investors Shouldn't Take Lightly at Motley Fool
Aug-19-15 06:29PM  Celgene May be The Single Best Biotech in the World
04:45PM  Amgen to pay $71 million to settle claims of off-label drug uses at bizjournals.com
Aug-18-15 11:45PM  Business Watch at The Wall Street Journal
10:31PM  Amgen to pay $71 million to states for promoting off-label drug uses at Los Angeles Times
07:00PM  Lightning Round: It had a great run, and now it's over at CNBC
07:00PM  Cramer: The wrong way to play a huge market trend
04:24PM  Amgen paying $71M in off-label drug marketing case
01:55PM  [$$] Amgen Reaches $71 Million Settlement With States at The Wall Street Journal
01:23PM  Five Reasons to Buy Biogen at Barrons.com
01:18PM  Amgen pays $71 mln to settle Enbrel, Aranesp marketing case Reuters
12:25PM  Amgen, U.S. states in $71 mln settlement over drug marketing Reuters
09:00AM  Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs PR Newswire
Aug-17-15 07:05PM  Horizon Pharmas Specialty Business Unit in 2Q15
05:09PM  Better Dividend Stock: Gilead Sciences Inc. vs. Amgen Inc. at Motley Fool
01:35PM  Healthy market spots
Aug-14-15 02:40PM  AMGN vs. GILD: The Battle of the Large Cap Biotech Stock
10:03AM  5 Things Amgen, Inc. Wants You to Know at Motley Fool
Aug-13-15 03:53PM  Some Positives Among The Carnage
11:42AM  Payers Set To Play Hardball On PCSK9 Pricing: RBC at Investor's Business Daily
Aug-12-15 02:52PM  3 Key Biotech Drug Approvals Expected This Month at Investor's Business Daily
12:18PM  Amgen: What If Generic Neulasta Gets Delayed Until Next Year? at Barrons.com
09:30AM  Regeneron Pharmaceuticals, Oshkosh, Amgen and Caterpillar highlighted as Zacks Bull and Bear of the Day
09:01AM  Bull of the Day: Regeneron Pharma (REGN)
08:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Aug-11-15 01:05PM  AMGEN INC Financials
11:42AM  Kite Pharma 2Q Loss Wider Than Expected, Pipeline in Focus - Analyst Blog
Aug-10-15 02:40PM  CVS, Express Scripts Pick Drugs to Restrict; Did Gilead's Sovalidi Make the Cut? at Barrons.com
01:31PM  Biotech: Is This the End of the Rally? at Barrons.com
12:24PM  Don't Give up on Biogen: Deutsche Bank Sees Fair Value at $400 at Barrons.com
11:43AM  Biotech Stocks Rise Due to a Stable Market: July 31 Week
Aug-08-15 08:10PM  10-Q for Amgen, Inc. at Company Spotlight
Aug-07-15 03:55PM  Will Kite Pharma (KITE) Miss Earnings Estimates Yet Again? - Analyst Blog
02:39PM  The Historical Correlation Between Biotech Stocks And Interest Rates
Aug-06-15 05:23PM  Allergan Q2 Beats, But Generics Sale Clouds Outlook at Investor's Business Daily
04:30PM  Expedia says Seattle campus could more than double in size at bizjournals.com
02:20PM  5 Big FDA Decisions Expected in August at 24/7 Wall St.
11:51AM  This Scary Event Has Happened 28 Times Since March 9, 2009 at Forbes
11:14AM  These Two Biotechs Boast Big EPS Growth Rates at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron, Baxalta and VIVUS - Press Releases
09:30AM  Allergan, it's not whether it's when: Faber
08:46AM  Dr. Reddys Announces Strategic Collaboration with Amgen in India Business Wire
08:41AM  3 Reasons Behind Amgen's 15% Gain in July at Motley Fool
08:33AM  Amgen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-05-15 02:58PM  What Company Will Be Fastest Growing Big-Cap Biotech? at Investor's Business Daily
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM